GB2251186A - Polypeptide for use in treatment of autoimmune disease - Google Patents
Polypeptide for use in treatment of autoimmune disease Download PDFInfo
- Publication number
- GB2251186A GB2251186A GB9026278A GB9026278A GB2251186A GB 2251186 A GB2251186 A GB 2251186A GB 9026278 A GB9026278 A GB 9026278A GB 9026278 A GB9026278 A GB 9026278A GB 2251186 A GB2251186 A GB 2251186A
- Authority
- GB
- United Kingdom
- Prior art keywords
- amino acid
- protein
- proteins
- sequences
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
Abstract
The use of a polypeptide comprising an amino acid sequence not homologous to a sequence synthesised by the cells of the patient, for the manufacture of a medicament for the treatment of an autoimmune disease is described.
Description
Auto immune Disease Treatment
This invention relates to the treatment of auto immune diseases, and especially the prophylactic treatment of such diseases.
Stress of a varied nature, induced as a result of heat shock, nutrient deprivation, oxygen radicals and other forms of metabolic disruption, including infection by certain viruses, bacteria and protozoans, as well as certain cases of cellular transformation, all lead to the increased synthesis of a family of proteins collectively known as stress proteins or heat shock proteins.
These stress proteins are among the most highly conserved and abundant proteins found in nature.
Further these proteins have been shown to be among the dominant antigens recognised in immune responses to a broad spectrum of pathogens. A review of the interrelationships between stress proteins, infection and immune surveillance has recently appeared, in which a clear analysis of these relationships is provided (13).
It has become apparent in recent years that a relationship exists between so-called stress or heat shock proteins and certain immune responses to infection and to the development of autoimmunity. As an example, the analysis of cell-mediated and humoral responses to a variety of bacterial and parasitic pathogens has shown that heat shock proteins are often strongly immunogenic during infection (1-8).
Proteins involved in immune responses to certain parasitic diseases such as malaria, shistosomiasis, leishmanisis, trypanosomiasis and filariasis, have been identified as members of the hsp 70 and 90 gene families. Further antigens related to hsp 70 and GroEL families have been shown to play a role in T cell and
B cell recognition during bacterial infections including leprosy, tuberculosis and Q. fever. The mycobacterial GroEL stress protein has been identified as the target of a T cell clone capable of causing autoimmune disease in a rat model of adjuvant-induced arthritis (9). Similar results have been obtained as concerns the small heat shock proteins, since an immunologically important 19 Kd protein antigen of
Mycobacterium leprae has been sequenced, and shown to have considerable amino acid sequence homology to the soybean l9Kd heat shock protein.
Elevated responses to the GroEL stress protein have been found by testing T cells from synovial infiltrates of rheumatoid arthritis patients (10). Autoantibodies to hsp 90 have been reported in systemic lupus erythrematosus (SLE) (11). In addition, elevated antibody responses to hsp70 and GroEL stress proteins have been found in SLE and in rheumatoid arthritis (12).
The stress proteins are remarkable in their evolutionary conservation: hsp90, hsp70, and hsp60 proteins are found in all prokaryotes and eukaryotes.
In fact comparison of almost any two hsp70 proteins from two different organisms indicates an amino acid homology of around 50%. The major stress proteins occur at low levels in normal, unstressed cells, but accumulate to very high levels in cells undergoing stress. A striking example is the case of E. coli hsp60, which accounts for 1.6% of total cell protein under normal growth conditions, and can accumulate to 15% of total cell protein after heat shock (14).
Stress proteins appear to fulfil vital roles in cells, both in the absence and in the presence of stress.
They appear to be involved in the assembly and disassembly of protein complexes, and hsp70 proteins are important for the translocation of certain proteins through cellular membranes (15). Stress proteins appear to interact with many different proteins, for example, hsp90 has been found to interact with steroid hormone receptors and with viral and cellular kinases. Hsp70 proteins bind to DNA replication complexes, clathrin baskets, the cellular tumour antigen p53, and immunoglobulin heavy chains.
Plant hsp60 interacts with Rubisco, which fixes C02 in chloroplasts, and may be the most abundant protein in the biosphere (16). The interaction of stress proteins with multiple proteins may provide an explication for the evolutionary constraints imposed on their amino acid sequences.
Stress proteins have an almost certain role in protecting cells and organisms from the deleterious effects of heat and other stresses.
It seems clear that the tight sequence regulation imposed on many heat shock protein sequences throughout evolution has led to such retained sequences between those of the host and those of the infectious agent having a significant degree of identity. Clearly the reaction of the host immune system against antigens of the infecting organism could lead to the raising of antibodies against heat shock proteins. The sequence homology within the heat shock protein family thus points to conserved sub-sequences of heat shock proteins as being serious candidates for inducing an immune response that can have specificity against self sequences, with the consequence of inducing an autoimmune reaction and the associated disease states.
The reports referenced above indicate that stress proteins, such as the heat shock proteins, provide particularly attractive targets for immune recognition.
An analysis the cross reactivity of T cell responses to stress proteins has been published recently (17), wherein the presence of human T cells was demonstrated that were capable of immune recognition of conserved sequence determinants. These authors have proposed a model in which immune responses to stress proteins provide a link between infectious and auto immune diseases.
Although models of the role of stress proteins in autoimmune diseases have been proposed, no-one has yet suggested possible treatment for autoimmune diseases.
In accordance with a first aspect of the present invention a method of treating an auto immune disease in a patient comprises introducing a compound, comprising an amino acid sequence of a protein which is not homologous with amino acid sequences synthesised by cells of the patient, into the patient.
In accordance with another aspect of the present invention there is provided use of a compound comprising an amino acid sequence of a protein for the treatment of an autoimmune disease in a patient, wherein the amino acid sequence is not homologous with amino acid sequences synthesised by cells of the patient.
Further, the invention provides a composition for treatment of an autoimmune disease in a patient, comprising a compound which comprises an amino acid sequence of a protein which is not homologous with amino acid sequences synthesised by cells of the patient, in combination with a pharmaceutical carrier.
Still further, the invention provides the use of a compound comprising an amino acid sequence of a protein which is not homologous with amino acid sequences synthesised by the cells of a patient for the manufacture of a medicament for the treatment of an autoimmune disease in the patient.
Preferably, the compound comprises a peptide which comprises the amino acid sequence and typically, the protein is a stress or heat shock protein.
Preferably, the treatment is prophylactic.
Typically, the compound could be introduced into a patient by incorporation in a cream or ointment, in a soluble glass, in slow release capsules, transdermal patches, injected, or even administered orally or in suppository form.
Preferably, the amino acid sequence has antigenic properties.
The amino acid sequence could be naturally occurring or be synthesised. If the amino acid sequence is synthesised then the peptide could comprise a number of different amino acid sequences and/or multiples of the same amino acid sequence.
The invention described here is based on the above-detailed conservation of heat shock sequences and their implication in autoimmune diseases. Contrary to the identity of certain conserved sequences, this invention, is based on the hypervariable sequences of stress proteins. Prior immunisation with natural or synthetic peptides representing such non-conserved, variable or hypervariable stress protein sequences of origin from infectious agents of bacterial and other parasitic pathogens, induces antibody responses against the stress proteins of the infecting organism, and these specifically induced antibodies are incapable of recognising self stress protein sequences.The rapid recognition of infectious agent - specific stress proteins by specific pre-existing antibodies raised against non-homologous peptides from invading stress proteins should allow the elimination of these stress proteins before they are able to elicit potentially autoimmune responses.
This invention concerns the immune recognition of peptide epitopes of specific heat shock or stress proteins, and the development of peptide-based therapy or prevention based on such epitopes.
Examples of the invention will now be described.
1. Analysis of stress protein peptide sequences
In order to practice the preventive/therapeutic approach described in this invention, it is necessary to examine in detail the amino acid sequences of human heat shock proteins, and of those of organisms infecting human beings with whom correlations of immune diseases exist.
Our initial approach was to assemble a table of certain of the known sequences of stress proteins from human and infectious agent sources. A selection of these sequences are presented in Appendix 1. A thorough analysis of sequence homology between members of each of the stress protein families indicates that for each of the principle stress protein families, hsp70, hsp90 and hsp27, certain sequences have been highly conserved throughout evolution, whereas parts of the stress proteins contain amino acid sequences that are highly differentiated. One assumes that the conservational pressures concerning the retained sequences are associated with critical structural or functional aspects of these important proteins.The variable regions are presumably of less critical structural or functional importance, thus escaping from the conservative pressure/selection activities prevailing in evolving organisms.
2. Selection of candidate peptide vaccines
The selection of useful candidate peptides capable of eliciting an immune response specifically against the stress proteins of the infectious agent is based on two major criteria: i) The non-identity of selected peptide sequences, and their lack of resemblance to highly, or partially conserved stress protein sequences, common to human and infectious agent proteins. The selection of such non-conserved sequences is derived from a reverse analysis of amino acid sequence homologies, in other words, concentrating on the non-homologous sequences evident from homology analyses such as those shown in (1) and in appendix 2.
For a thorough selection of sequence differences versus sequence homology, it is instructive to, in addition to amino acid identity, to look at replacements by highly conserved amino acids. Examples of such substitutions are the following groups: (aspartic acid and glutamic acid), (lysine and arginine), (serine and threonine), (phenylalanine and tyrosine), and (isoleucine, leucine, valine and methionine).
ii) An analysis of the antigenic potential of selected peptide sequences. Where information is available, peptide epitopes that conform to the criteria of both points i) and ii), and which can be demonstrated to be immunodominant, are preferred examples of the preventive/therapeutic peptides described in this invention.
Examples of the amino acid sequences of some selected peptides that reply to the criteria of point i) are presented in appendix 2.
Examples of group i) peptides that are expected to have considerable immunogenic potential have been selected on the basis of presently accepted criteria of immunological potential. Examples of certain peptides with pronounced antigenicity are shown in appendix 3.
Non-homologous sequence comparison of the known stress protein and related antigen sequences from humans and from infectious agents has been performed. In the case of Plasmodium falciparum, in addition to regions of extensive homology of amino acid sequence between the two proteins, clear regions of extensive lack of homology are also detectable, and the following sequence fragments, depicted using the one and three-letter amino acid abbreviations derived from the
IUPAC-IUB Commission on Biochemical Nomenclature (see
Table 1), illustrate this example::
ALIGNMENT OF RESIDUES 133 TO 254 OF 75KDa antigen of P Falciparum TO RESIDUES 357 TO 635 OF HSP70 HUMAN
ENYCYGVKSSLEDKIKEKLQPAEIETCMKTITTILEWLEKNQLAGKDEYE ------------ KNALES-Y-AFNMKSA- VEDEG LKGKIS-E
AKQKEAESVCAPIMSKIY-QDAA-GAAGGMPGGM-P-GGMPGGMP GGMNF
ADKKKVLDKCQEVIS- WLDANTLA EKDEFEHKRKELEQVCNPIISGL-Y pG-GMpG-AGMpGNAp---AGSGpTVEEVV QGAGGPGPGGFGAQGPKGGSGSGPT----
Examples of non-homologous peptides are shown in bold letters. The second peptide of HSP70 human shown in bold above, denoted "Peptide example 1", has been compared to the sequence of the corresponding antigen of Mycobacterium tuberculosis and its highly unique sequence has little or no counterpart in the sequence of tubercular origin.
ALIGNMENT OF RESIDUES 8 TO 11 OF PEPTIDE 1 TO RESIDUES 1 TO 127 OF 71KDa antigen M.tuberculosis K----R--K-- E --------------------------------'----
KEDIDRMIKDAEAHAEEDRKRREEADVRNGAETLVYNTEKFVKEQREGG
Clearly other peptide sequences unique to an infectious agent antigen exist and will have value in the applications described in this invention. In order to identify such sequences, extensive cloning, expression and sequence analysis of infectious agent antigens will be required. Such research, although technically arduous, is quite within the realms of existing technology. Similarly, once new sequences are established, the presence or absence of amino acid sequence homologies can be determined either visually, or through the use of any number of amateur or commercial sequence analysis software programs. Our intention here is to demonstrate the general procedure for identifying, and applying both specific non-homologous and specific homologous stress and infectious agent antigen peptide sequences to the vaccination, therapeutic and cosmetic applications described herein.
3 The Rational Design of Synthetic Peptides This invention is not limited to naturally occurring variant sequences within stress proteins, nor is it limited to the selection and use of a single variant epitope. For example, synthetic peptides could be used. In addition, the peptide could be synthesised to have combinations of different variant sequences or multiples of variant sequences. By synthesising peptides comprising different variant sequences and/or multiples of the same variant sequence it may be possible to design peptides having a stronger immune response against stress proteins of infectious organisms but which do not recognise human stress epitopes.
A recent analysis of variant peptide epitopes of myelin basis protein (MBP), and their influence on the incidence of experimental autoimmune encephalomyelitis (EAE) has indicated that synthetic variants of an
N-terminal MBP peptide can have greatly altered properties of binding to cell surface glycoproteins encoded by the major histocompatibility complex (MHC) (18). In other words, the efficacy of the complex interactions associated with the elicitation of an effective immune response against peptide antigens, can be altered and improved in some cases, by the use of synthetic variants of natural antigens. The subject of this invention comprises those variant peptide sequence approaches that are taught by the authors of reference 18, amongst others.
An efficient mapping procedure for identifying protein antigenic determinants has been described that would be of use in the selection of useful antigenic determinants for the applications taught in this invention (19). Clearly classical chemical, enzymatic and combined synthetic procedures can be utilised to produce candidate peptides, once identified and selected, for the vaccine applications described here.
A naturally expected limitation of the peptide vaccines that can be produced using this described procedure derives from the fact that about one third of monoclonal and polyclonal antibodies made by immunising with native protein react with assembled topographic sites (20). These assembled determinants may not form the appropriate structure outside of a proteins native environment. This limitation is not expected to significantly limit the practical use of this invention.
Studies concerning T Cell recognition and activation have indicated that it may be possible to design peptides with predictable and advantageous properties (21). These authors have described two approaches for immunomodulation that could be useful for the design of therapeutic strategies against autoimmune encephalomyelitis. The first approach consists of a thorough molecular characterisation of an encephalitogenic epitope, and the subsequent design of peptide analogs that retain normal or increased major histocompatibility complex binding properties, and that fail to activate disease-inducing T cells. Secondly, novel properties of a heterocyclic peptide have been described, with the result that the peptide is highly antigenic in vitro, while being non-immunogenic in vivo.These authors have been able to demonstrate the feasibility of immune intervention in an immune disease through the use of a synthetic peptide. These results are complementary to the procedure we describe here, but are not identical, nor do they in any way predict the approach that we describe.
4 Applications of the stress protein peptides described herein
The basic tenant that we have developed herein is based on the multiple observations that certain infectious agent antigens are closely related in amino acid sequence to human stress proteins, and that immune reactions against such antigens can cross react with the human proteins, leading to the possibility of developing autoimmune disease. Our invention describes the selection of stress protein peptide sequences from infectious agent antigens related to human stress proteins, but which have little or no sequence homology within such human stress proteins. The injection of such non-homologous peptides into human beings, for instance in an emulsification with Freunds complete adjuvant, would provide a route of effective vaccination against subsequent auto immune disease induced as mentioned above.The antibodies raised through such vaccination are specific to the selected infectious agent antigen from which the vaccinating peptide was derived. Such induced antibodies are specific te infectious agent antigens, thus explaining their efficacy in the application of this invention.
Further, since the vaccinating agent is a small peptide, instead of a large, complex protein such as human factor VIII, or factor IX, it is not compulsory to use an injection as a means of delivering the peptide to a human subject. We thus reserve in our application the administration of the kinds of peptides described by transdermal applications, a number of which are presently commercialised with considerable success.
Further still, since certain major diseases that are thought to have their origin in autoimmune diseases, such as arthritis and rheumatism, the peptides of this invention can be applied externally, in both local and cosmetic application to painful joints and articulations resulting from these prevalent diseases.
For example, the peptides could be administered to a patient by incorporation in a cream or ointment, in a soluable glass, in slow release capsules, transdermal patches, injected, or even administered orally or in suppository form.
In addition, due to the nature of amino acid sequences it is unlikely that treatment using these substances will produce the unpleasant side effects which are normally associates with drugs.
APPENDIX 1
NON-HOMOLOGOUS SEQUENCES WHICH ARE ALSO
KNOWN ANTIGENICS ARE DENOTED BY
UNDERLINING AND NON-HOMOLOGOUS ONLY
SEQUENCES ARE DENOTED BY BOLD LETTERING
SEQUENCE OF HUMAN STRESS PROTEINS
A) Sequence HSP90 Human
Rebbe N F, Ware J, Bertina M, Modrich P, Stafford D W
Gene 53:235-245(1987)
EMBL; M16660; HSHSP90
KW Heat Shock. Sequence 724 AA; 83293 MW
MPEEVHHGEE EVETFAFQAE IAQLMSLIIN TFYSNKEIFL 40
RELISNASDA LDKIRYESLT DPSKLDSGKE LKIDIIPNPQ 80
ERTLTLVDTG IGMTKADLIN NLGTIAKSGT KAFMEALQAG 120
ADISMIGQFG VGFYSAYLVA EKVVVIRKHN DDEQYAWESS 160
AGGSFTVRAD HGEPIGMGTK VILHLKEDQT EYLEERRVKE 200
VVKKHSQFIG YPITLYLEKE REKEISDDEA EEEKGEKEEE 240
DKDDEEKPKI EDVGSDEEDD SGKDKKKKTK KIKEKYIDQE 280
ELNKTKPIWT RNPDDITQEE YGEFYKSLTN DWEDHLAVKH 320
FSVEGQLEFR ALLFIPRRAP FDLFENKKKK NNIKLYVRRV 360
FIMDSCDELI PEYLNFIRGV VDSEDLPLNI SREMLQQSKI 400
LKVIRKNIVK KCLELFSELA EDKENYKKFY EAFSKNLKLG 440
IHEDSTNRRR LSELLRYHTS QSGDEMTSLS EYVSRMKETQ 480
KSIYYITGES KEQVANSAFV ERVRKRGFEV VYMTEPIDEY 520
CVQQLKEFDG KSLVSVTKEG LELPEDEEEK KKMEESKAKF 560
ENLCKLMKEI LDKKVEKVTI SNRLVSSPCC IVTSTYGWTA 600
NMERIMKAQA LRDNSTMGYM MAKKHLEINP DHPIVETLRQ 640
KAEADKNDKA VKDLVVLLFE TALLSSGFSL EDPQTHSNRI 680
TYMIKLGLGI DEDEVAAEEP NAAVPDEIPP LEGDEDASRM 720
EEVD 724
B) Sequence HSP70 Human [1] Hunt C, Morimoto R I;
Proc Natl Acad Sci USA 82:6455-6459(1985)
EMBL; M11236; HSHSP701
EMBL; MII717; HSHSP70D
KW Heat Shock
Sequence 640AA; 69867 MW
MAKAAAVGID LGTTYSCVGV FQHGKVEIIA NDQGNRTTPS 40
YVAFTDTERL IGDAAKNQVA LNPQNTVFDA KRLIGRKFGD 80 PVVQSDMKHW PFQVINDGDK PKVQVSYKGE TKAFYPEEIS 120
SMVLTKMKEI AEAYLGYPVT NAVITVPAYF NDSQRQATKD 160
AGVIAGLNVL RIINEPTAAA IAYGLDRTGK GERNVLIFDL 200
GGGTFDVSIL TIDDGIFEVK ATAGDTHLGG EDFDNRLVNH 240 (3)
FVEEFKRKHK KDISQNKRAV RRLRTACERF EGIDFYTSIT 280
RARFEELAKR TLSSSTOASL EIDSLCSDLF RSTLEPVEKA 320 (4)
LRDAKLDKAQ IHDLVLVGGS TRIPKVQKLL QDFFNGRDLN 360
KSINPDEAVG YGAAVQAAIL MGDKSENVQD LLLLDVAPLS 400
LGLETAGGVM TALIKRNSTI PTKQTQIFTT YSDNQPGVLI 440 QVYEGERAHT KDNNLLGRFE LSGIPPAPGV PQIEVTFDID 480 (1)
ANGILNVTAT DKSTGKANKI TITNDKGRLS KEEIERI4VQE 520
AEKYKAEDEV QRERVSAKNA LESYAFNMKS AVEDEGLKGK 560 (2)
ISEADKKKVL DKCQEVISWL DANTLAEKDE FEHKRKELEQ 600
VCNPIISGLY QGAGGPGPGG FGAQGPKGGS GSGPTIEEVD 640
C) Sequence Human HSP27
Hickey E, Brandon S E, Potter R, Stein G, Stein J,
Weber L A;
Nucl.Acids Res 14:4127-4145(1986)
EMBL;X03900; HSHSP27
KW: HEAT SHOCK
SEQUENCE 199 AA; 22327 MW;
MTERRVPFSL LRGPSWDPFR DWYPHSRLFD QAFGLPRLPE 40
EWSQWLGGSS WPGYVRPLPP AAIESPAVAA PAYSRALSRQ 80
LSSGVSEIRH TADRWRVSLD VNHFAPDELT VKTKDGVVEI 120
TGKHEERQDE HGYISRCFTR KYTLPPGVDP TQVSSSLSPE 160
GTLTVEAPMP KLATQSNEIT IPVTFESRAQ LGGRSCKIR 200
D) Sequence Human HSP60
Sequence not yet available, submitted for publication:
Gupta R S, Jinal S, Harley C B and Dudani A K(1989)
SEQUENCE OF HSP60 YEAST
Reading D S, Hallberg R L and Myers A M (1989).Nature 337 655 MLRSSVVRSR ATLRPLLRRA YSSHKILKFG VIGRASLLKG 40
VETLAIAVAA TLGPKGRNVL IEQPFGPPKI TKDGVTVAKS 80
IVLKDKFINM GAKLLQIVAS KTNIAAGDGT TSATVLGRAI 120
FTISVKNVAA GCNPMDLRRG SQVAVIKVIL FLSANKKEIT 160
TSEEIAQVAT ISANGDSHVG KLLASAMEKV GKEGVITIRE 200
GRITLEDELE VTEGMRFDRG FISPYFITDP KSSKVEFEKP 240
LLLLSEKKIS SIQDILPALE ISNQSRRPLL IIAEDVDGEA 280
LAACILNKLR GQVKVCAVKA PGFGDNRKNT IGDIAVLTGG 320
TVFTEELDLK PEQCTIENLG SCDSITVTKE DTVILNGSGP 360
KEAIQERIEQ IKGSIDITTT NSYEKEKLQE RLAKLSGGVA 400
VIRVGGASEV EVGEKKDRYD DALNATRAAV EEGILPGGGT 440
ALVKASRVLD EVVVDNFDQK LGVDIIRKAI TRPAKQIIEN 480
AGEEGSVIIG KLIDEYGDDF AKGYDASKSE YTDMLATGII 520
DPFKVVRSGL VDASGVASLL ATTEVAIVDA PEPPAAAGAG 560
GMPGGMPG MPGMM 600
SEQUENCES OF BACTERIAL ANTIGENS
A) Mycobacterium leprae 18 KDa Antigen
Nerland A H, Mustapha A S, Sweetser D, Godal T, Young R
J Bacteriol 170 5919-5921 (1988)
Sequence 148 AA; 16643MW;
MLMRTDPFRE LDRFAEQVLG TSARPAVMPM DAWREGEEFV 40
VGFDLPGKA DSLDIDIERD VVTVRAERPG VDPDREMLAA 79
ERPRGVFNRQ LVLGENLDTE RILASYQEGV LKLSIPVAER 119
AKPRKISVDR GNNGHQTINK TPHEIIDA 65 KDa Antigen
Mehra V, Sweetser D and Young R A (1986) Proc Natl Acad
Sci USA 83 7013
AA 589, MW 61,831
The Underling Amino Acids Correspond To Antigenic
Peptides.
VPGRDGETQP ASCGRPSRAL HPASVSNGGC RSPVILASFL 40
IRRNHFAMAK TIAYDEEARR GLERGLNSLA DAVKVTLGPK 80
GRNVVLEKKW GAPTITNDGV SIAKEIELED PYEKIGAELV 120
KEVAKKTDDV AGDGTTTATV LAQALVKEGL RNVAAGANPL 160
GLKRGIEKAV DKVTETLLKD AKEVETKEQI AATAAISAGD 200
QSIGDLIAEA MDKVGNEGVI TVEEESNTFG LQLELTEGMR 240
FDKGYISGYF VIDAERQEAV LEEPYILLVS SKVSTVKDLL 280
PLLEKVIQAG KSLLIIAEDV EGEALSTLW NKIRGTFKSV 320
AVKAPGFGDR RKAMLQDMAI LTGAQVISEE VGLTLENTDL 360
SLLGKARKVV MTKDETTIVE GAGDTDAIAG RVAQIRTEIE 400
NSDSDYDREK LQERLAKLAG GVAVIKAGAA TEVELKERKH 440
REIDAVRNAK AAVEEGIVAG GGVTLLQAAP ALDKLKLTGD 480
EATGANIVKV ALEAPLKQIA FNSGMEPGVV AEKVRNLSVG 520
HGLNAATGEY EDLLKAGVAD PVKVTRSALO NAASIAGLFL 560 TTEAVVADKP EKTAAPASDP TGGMGGMDF 600 70 KDa Antigen
Not yet sequenced.Immunological cross-reactivity with the 71 KDa antigen of Mycobacterium tuberculosis (YOUNG
ET AL Proc Natl Acad Sci USA 85, 4267-4270 (1988).
B) Mycobacterium tuberculosis 65 KDa Antigen
Schinnick, T S (1987). Journal of Bacteriology 169 1080
AA 562, MW 59083
RGCRHPVTPP VSSPIRRNHF AMAKTIAYDE EARRGLERGL 40
NALADAVKVT LGPKGRNVVL EKKWGAPTIT NDGVSIAKEI 80
ELETPYEKIG AELVKEVAKK TDDVAGDGTT TATVLAQALV 120
REGLRNVAAG ANPLGLKRGI EKAVEAKVTET LLKGAKEVET 160
KEQIAATAAI SAGDQSIGDL IAEAMDKVGN EGVITVEESN 200
TFGLQLELTE GMRFDKGYIS GYFVTDPERQ EAVLEDPYIL 240
LVSSKVSTVK DLLPLLEKVI GAGKPLLIIA EDVEGEALST 280 LVVNKIRGTF KSVAVKAPGF GDRRKAMLQD MAILTGGQVI 320
SEEVGLTLEN ADLSLLGKAR KVVVTKDETT IVEGAGDTDA 360
IAGRVAQIRQ EIENSDSDYD REKLQERLAK LAGGVAVIKA 400
GAATEVELKE RKHRIEDAVR NAKAAVEEGI VAGGGVTLL 440
AAPTLDELKL EGDEATGANI VKVALEAPLK QIAFNSGLEP 480 GVVAEKVRNL PAGHGLNAQT GVYEDLLAAG VADPVKVTRS 520
ALQNAASAIG LFLTTEAVVA DKPEKEKASV PGGGDMGGMD 560
F 600 71 KDa Antigen
Partial sequence, contains only the homolgy domain with
HSP70
Young D, Lathigra R, Hendrix R, Sweetser D, Young R,
Proc Acad Sci
USA 85, 4265-4270 (1988).
EFQPSVQIQV YQGEREIAAH NKLLGSFELT GIPPAPRGIP 40 (1)
QIEVTFDIDA NGIVHVTAKD KGTGKENTIR IQEGSGLSKE 80
DIDRMIKDAE AHAEEDRKRR EEADVRNGAE TLVYNTEKFV 120 3,4
KEQREGGSKV PEDTWRIGYF GHQVGDGEAG PGVAGSGASD 160 (2)
LRSSSGCVTG HWRCPPRAAA GRCPPRLGM 200
C) Plasmodium falciparum (MALARIA) 90 KDa Antigen
M Jendoubi, S Bonnefoy, Nucl Acids Res 16, 10928 (1988)
Partial sequence, contains only the region of homology with HSP90
KDFDGKKLKC CTKEGLDIHH SEEAKKDFET VIKDVLHKKV 40 EKVVVCQRIT DSPCVLVTSE FGWSANMERI MKAQALRDNS 80
MTSYMLSKKI MEINARHPII SALKQKADAD KSDKTVKYLI 120
WLLFDTSLLT SGFFALEEPT TFSKRIHRMI KLGLSIDEEE 160
NNDIDLPPLE ETVDATDSKM EEVD 200 75 KDa Antigen
Ardeshir F, Flint J E, Richman S and Reese R T, Embo J.
6, 493-499 (1987).
Partial sequence from the first AA
MLKLIERNTT IPAKKSQIFT TYADNQPGVL IQVYEGERAL 40
TKDNNLLGKF HLDGIPPAPR KVPQIEVTFD IDANGILDVT 80
AVEKSTGKQN HITITNDKGR LSQDEIDRMV NDAEKYLAED 120
EENRKRIEAR NSLENYCYGV KSSLEDKIKE KLQPAEIETC 160
MKTITTILEW LEKNQLAGKD EYEAKQKEAE SVCAPIMSKI 200
YQDAAGAAGG MPGGMPGGMP GGMPGGMNFP GGMPGAGMPG 240
NAPAGSGPTV EEVVD 280
APPENDIX 2
DIFFERENTIATION OF HOMOLOGOUS (UNDERLINE)
AND NON-HOMOLOUGOS SEQUENCES
A) Alignment of Residues 47 to 161 of partial sequence of P.Falciparum 90KD to residues 581 to 699 of human
HSP90 --RI-DSPCVLVTSEFGWSANMERIMKAOALRDNSMTSYMLSKKIMEINAR NRLVSSPCCIVTSTYGWTANMERIMKAQALRDNSTMGYIMAKKHLEINPD HPIISALKDADKSDKTVKYLIWLLFDTSLLTSGFFALEEPTTFSKRI HPIVETLRQKAEADKNDKAVKDL W LLFETALLSSG-FSLEDPQTHSNRI HRMIKLGLSIDEEE---NN
YRMIKLGLGIDEDEVAAEE
B) Alignment of residues 7 to 157 of partial sequence of P. falciparum 70 KDa to residues 411 to 613 of human
HSP70.
NTTIPAKKSOIFTTYADNOPGVLIOVYEGERALTKDNNLLGKFHL
ALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFEL
DGIPPAPRKVPOIEVTFDIDANGILDVTAVEKSTGKQNHITITNDKGRLS
SGIPPAP-GVPQIEVTFDIDANGILNVTATDKSTGKMWITITNDKDRLS
QDEIDRMVNDAEKYLAEDEENRKRIEARNSLENYCYGVKSSLEDM-IKEKLQ KEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKIS P~ETCMK---TITTILEWLEK~QLAGKDEYEAKQKEAES~CAPIMSKIYQDA EADKKKVLDKCQEVI-SWLDANTLAEKDEFEHKRKELEQVCNPIISGLYQGA
C) Alignment of residues 5 to 110 of M tuberculosis 71K to residues 430 to 548 of human HSP70 VQIOVYQGEREIAAHNKLLGSFELTGIPPAPRGIPOIEVTFDI YSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAP-GVPQIEVTFDI
DANGIVHVTAKDKGTGKENTIRIQEGSG-LSKEDIDRMIKDAEAHAEEDR DANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDE KRREEADVRNGAE-----
VQRERVSAKNALESYAFNM
APPENDIX 3
Antigenic peptides of the 65 Kda Antigen of
Mvcobacterium leprae
MEHRA V, SWEETSER D and YOUNG R A (1986) Proc Natl Acad
Sci USA 83 7013 -NSLADAVKVTLGPKGRNVVLEKKWGAPTITNDGVS -RNVAAGANPLGLKRGIEKAV -ALDKLKLTGDEATGA -GEYEDLLKAGVADP -ASDPTGGMGGMDF
TABLE 1
One and Three Letter Amino Acid Abbreviations
A Ala Alanine
C Cys Cysteine
D Asp Aspartic acid
E Glu Glumatic acid
F Phe Phenylalanine
G Gly Glycine
H His Histidine
I Ile Isoleucine
K Lys Lysine
L Leu Leucine
M Met Methionine
N Asn Asparagine
P Pro Proline
Q Gln Glutamine
R Arg Arginine
S Ser Serine
T The Threonine
V Val Valine
W Trp Tryptophane
Y Tyr Tyrosine
B Asx Asp or Asn (not
distinguished)
Z Glx Glu or Gln (not
distinguished)
X X Undetermined or atypical
amino acid
From: IUPAC-IUB Commission on Biochemical
Nomenclature, J Biol
Chem 243, 3557-3559, 1968.
References 1 Young D B, Lathigra R, Hendrix R, Sweetser D and
Young R A 1988. Stress proteins are immune targets in leprosy and tuberculosis. Proc Natl Acad Sci USA 85 4267.
2 Vodkin M H and Williams J C 1988. A heat shock operon in Coxiella burnetti produces a major antigen homologous to a protein in both mycobacteria and
Escherichia coli. J Bacteriol 170 1227.
3 Bianco A E, Favaloro J M, Burkot T R, Culvenor J
G, Crewther P E, Brown G V, Anders R F, Coppel R L and
Kemp D J 1986. A repetitive antigen of Plasmodium falciparum that is homologous to heat shock protein 70 of Drosophila melanogaster. Proc Natl Acad Sci USA 83 8713.
4 Ardesshir F, Flint J E, Richman S J and Reese R T 1987. A 75Kd merozile surface protein of Plasmodium falciparum which is related to the 70 Kd heat-shock proteins. EMBO J 6 493.
5 Hedstrom R, Culpepper J, Harrison R A, Agabian N and Newport G 1987. A major immunogen in Schistosoma mansoni infections is homologous to the heat-shock protein Hsp 70. J Exp Med 165 1430.
6 Selkirk M E, Rutherford P J, Denham D A, Partano F and Maizels R M 1987. Cloned antigen genes of Brugia filarial parasites. Biochem Soc Symp 53 91.
7 Dragon E A, Sias S R, Kato E A and Gabe J D 1987.
The genome of Trypanosoma cruzi contains a constitutively expressed tandemly arranged multicopy gene homologous to a major heat shock protein. Mol
Cell Biol 7 1271.
8 Jendoub M and Bonneloy S 1988. Identification of a heat shock-like antigen in P. falciparum related to the heat shock protein 90 family. Nucleic Acids Res 16 10928.
9 van Eden W, Thole J E R, van der Zee R, Noordzy A, van Embden J D A, Hensen E J and Cohen I R 1988.
Coning of the mycobacterial epitope recognised by T lymphocytes in adjuvant arthritis. Nature 331 171.
10 Res P C M, Schaar C G, Breedveld F C, van Eden W, van Embden J D A, Cohen I R and de Vries R R P 1988.
Synovial fluid T cell reactivity against 65 Kd heat shock protein of mycobacteria in early chronic arthritis. Lancet 478.
11 Minota S, Koyasu S, Yahara and Winfield J 1988.
Autoantibodies to the heat shock protein hsp90 in systemic lupus erythrematosus. J Clin Invest 81 106.
12 Tsoulfa G, Rook G A W, van Embden J D A, Young D
B, Mehlert A, Isenberg D A, Hay F C and Lydyard P M 1989. Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis. Annals of Rheumatic Diseases. 48 118.
13 Young R A and Elliot T J 1989. Stress Proteins,
Infection, and Immune Surveillance. Cell 59 5 14 Herendeen S L, van Bogelen R A and Neidhardt F C 1979. J Bacteriol 139 185.
15 Cheng M Y, Hartl F -U, Martin J, Pollock R A,
Kalousek F, Neupert W, Hallberg E M, Hallberg R L and
Horwich A L 1989. Nature 337 620.
16 Hemmingsen S M, Woolford C, van der Vies S , Tilly K, Dennis D T, Georgopoulos C P, Hendrix R W and
Ellis R J 1988. Nature 333 330.
17 Lamb J R, Bal V, Mendez-Samperio P, Mehlert A, So
A, Rothbard J, Jindal S, Young R A and Young D B 1989.
Stress proteins may provide a link between the immune response to infection and autoimmunity. The Japanese
Society for Immunology 0953 8178/89, International
Immunology Vol 1 No 2.
18 Urban J L, Horvath S J and Hood L 1989.
Auto immune Recognition of Normal and Variant Peptide
Epitopes and Peptide-Based Therapy. Cell 59 257.
19 Mehra V, Sweetser D and Young R A 1986. Efficient mapping of protein antigenic determinants. Proc Natl
Acad Sci USA 83 7013.
20 Berzofsky J A 1985. Science 229 932 21 Wraith D C, Smilek D E, Mitchell D J, Steinman L and McDevitt H 0 1989. Cell 59 247.
Claims (4)
1. A method of treating an autoimmune disease in a
patient comprises introducing a compound,
comprising an amino acid sequence of a protein
which is not homologous with amino acid sequences
synthesised by cells of the patient, into the
patient.
2. Use of a compound comprising an amino acid
sequence of a protein for the treatment of an
autoimmune disease in a patient, wherein the amino
acid sequence is not homologous with amino acid
sequences synthesised by cells of the patient.
3. A composition for treatment of an autoimmune
disease in a patient, comprising a compound which
comprises an amino acid sequence of a protein
which is not homologous with amino acid sequences
synthesised by cells of the patient, in
combination with a pharmaceutical carrier.
4. The use of a compound comprising an amino acid
sequence of a protein which is not homologous with
amino acid sequences synthesised by the cells of a
patient for the manufacture of a medicament for
the treatment of an auto immune disease in the
patient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9026278A GB2251186A (en) | 1990-12-04 | 1990-12-04 | Polypeptide for use in treatment of autoimmune disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9026278A GB2251186A (en) | 1990-12-04 | 1990-12-04 | Polypeptide for use in treatment of autoimmune disease |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9026278D0 GB9026278D0 (en) | 1991-01-23 |
GB2251186A true GB2251186A (en) | 1992-07-01 |
Family
ID=10686409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9026278A Withdrawn GB2251186A (en) | 1990-12-04 | 1990-12-04 | Polypeptide for use in treatment of autoimmune disease |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2251186A (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995025531A1 (en) * | 1994-03-18 | 1995-09-28 | Ivan Nikolaevich Golovistikov | Means for treating auto-immune diseases and method of treatment |
WO1996016083A1 (en) * | 1994-11-21 | 1996-05-30 | Italfarmaco S.P.A. | Peptides endowed with antiinflammatory activity |
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
WO1998042366A1 (en) * | 1997-03-25 | 1998-10-01 | Zetesis S.P.A. | The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf) |
US5830464A (en) * | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US5837251A (en) * | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5948646A (en) * | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
US5961979A (en) * | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US5985270A (en) * | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US6017540A (en) * | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
US6040187A (en) * | 1994-03-18 | 2000-03-21 | Ivan Nikolaevich Golovistikov | Method of determining the suppressor cell component of human immune status and a means for the realization thereof |
US6335183B1 (en) | 1988-06-15 | 2002-01-01 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US6495347B1 (en) | 1999-07-08 | 2002-12-17 | Stressgen Biotechnologies Corporation | Induction of a Th1-like response in vitro |
US6497880B1 (en) | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
US6524825B1 (en) | 1997-08-05 | 2003-02-25 | Stressgen Biotechnologies, Inc. | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
US6797491B2 (en) | 2000-06-26 | 2004-09-28 | Stressgen Biotechnologies Corporation | Human papilloma virus treatment |
US6875435B2 (en) | 2000-01-14 | 2005-04-05 | Whitehead Institute For Biomedical Research | In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
US6921534B2 (en) | 2001-02-05 | 2005-07-26 | Stressgen Biotechnologies Corporation | Hepatitis B virus treatment |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
US7449557B2 (en) | 2000-06-02 | 2008-11-11 | University Of Connecticut Health Center | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
US7666581B2 (en) | 2001-08-20 | 2010-02-23 | University Of Connecticut Health Center | Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease |
US8475785B2 (en) | 2008-03-03 | 2013-07-02 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
US8541002B2 (en) | 2003-09-12 | 2013-09-24 | Agenus Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
US8685384B2 (en) | 1998-02-20 | 2014-04-01 | University Of Miami | Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex |
US8968720B2 (en) | 2008-03-20 | 2015-03-03 | University Of Miami | Heat shock protein GP96 vaccination and methods of using same |
US10046047B2 (en) | 2015-02-06 | 2018-08-14 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985005034A1 (en) * | 1984-04-27 | 1985-11-21 | University College London | Compositions for the allevation, treatment and diagnosis of arthritic disease and related conditions |
WO1988010120A1 (en) * | 1987-06-24 | 1988-12-29 | Brigham And Women's Hospital | Treatment of autoimmune diseases by oral administration of autoantigens |
EP0322990A1 (en) * | 1987-12-22 | 1989-07-05 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions |
GB2221157A (en) * | 1988-07-21 | 1990-01-31 | Biogal Gyogyszergyar | Intravenous pharmaceutical composition comprising cyclosporin |
-
1990
- 1990-12-04 GB GB9026278A patent/GB2251186A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985005034A1 (en) * | 1984-04-27 | 1985-11-21 | University College London | Compositions for the allevation, treatment and diagnosis of arthritic disease and related conditions |
WO1988010120A1 (en) * | 1987-06-24 | 1988-12-29 | Brigham And Women's Hospital | Treatment of autoimmune diseases by oral administration of autoantigens |
EP0322990A1 (en) * | 1987-12-22 | 1989-07-05 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions |
GB2221157A (en) * | 1988-07-21 | 1990-01-31 | Biogal Gyogyszergyar | Intravenous pharmaceutical composition comprising cyclosporin |
Non-Patent Citations (3)
Title |
---|
Autoimmunity 1990, 7, 237-244 * |
Clin.exp.Immunol. 1990, 81, 189-194 * |
Immunology 1969, 16(2), 157-165 * |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6482614B1 (en) | 1988-06-15 | 2002-11-19 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US6335183B1 (en) | 1988-06-15 | 2002-01-01 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US7501234B2 (en) | 1989-06-15 | 2009-03-10 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US6468540B1 (en) | 1994-01-13 | 2002-10-22 | Mount Sinai School Of Medicine Of New York University | Immunotherapeutic stress protein-peptide complexes against cancer |
US6017544A (en) * | 1994-01-13 | 2000-01-25 | Mount Sinai School Of Medicine Of The University Of New York | Composition comprising immunogenic stress protein-peptide complexes against cancer and a cytokine |
US6610659B1 (en) | 1994-01-13 | 2003-08-26 | Mount Sinai School Of Medicine Of New York University | Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease |
US6455503B1 (en) | 1994-03-16 | 2002-09-24 | Mount Sinai School Of Medicine Of New York University | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US5961979A (en) * | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US6048530A (en) * | 1994-03-16 | 2000-04-11 | Mount Sinai School Of Medicine Of New York University | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
WO1995025531A1 (en) * | 1994-03-18 | 1995-09-28 | Ivan Nikolaevich Golovistikov | Means for treating auto-immune diseases and method of treatment |
US6150326A (en) * | 1994-03-18 | 2000-11-21 | Leonid Yazonovich Kacharava | Means for treating autoimmune diseases and method for the treatment thereof |
US6040187A (en) * | 1994-03-18 | 2000-03-21 | Ivan Nikolaevich Golovistikov | Method of determining the suppressor cell component of human immune status and a means for the realization thereof |
WO1996016083A1 (en) * | 1994-11-21 | 1996-05-30 | Italfarmaco S.P.A. | Peptides endowed with antiinflammatory activity |
US6162436A (en) * | 1995-09-13 | 2000-12-19 | Fordham University | Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases |
US6187312B1 (en) | 1995-09-13 | 2001-02-13 | Fordham University | Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of infectious diseases |
US6139841A (en) * | 1995-09-13 | 2000-10-31 | Fordham University | Compositions and methods using complexes of heat shock protein 70 and antigenic molecules for the treatment and prevention of infectious diseases |
US6143299A (en) * | 1995-09-13 | 2000-11-07 | Fordham University | Compositions and methods using complexes of heat shock protein gp96 and antigenic molecules for the treatment and prevention of infectious diseases |
US6030618A (en) * | 1995-09-13 | 2000-02-29 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US6156302A (en) * | 1995-09-13 | 2000-12-05 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US6410028B1 (en) | 1995-09-13 | 2002-06-25 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US6136315A (en) * | 1995-09-13 | 2000-10-24 | Fordham University | Compositions and methods using complexes of heat shock protein 70 and antigenic molecules for the treatment and prevention of neoplastic diseases |
US5985270A (en) * | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US7601359B1 (en) | 1995-09-13 | 2009-10-13 | Fordham University | Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins |
US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US6461615B1 (en) | 1995-09-13 | 2002-10-08 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US5837251A (en) * | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
US6447781B1 (en) | 1995-09-13 | 2002-09-10 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
US6436404B1 (en) | 1997-02-07 | 2002-08-20 | Fordham University | Prevention of primary and metastatic neoplastic diseases with GP96-peptide complexes |
US6017540A (en) * | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
US6403095B1 (en) | 1997-02-07 | 2002-06-11 | Fordham University | Treatment of primary and metastatic neoplastic diseases with HSP70-peptide complexes |
US5830464A (en) * | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6399070B1 (en) | 1997-02-07 | 2002-06-04 | Fordham University | Methods and compositions for eliciting an immune response with hsp90-peptide complexes |
US6387374B1 (en) | 1997-02-07 | 2002-05-14 | Fordham University | Treatment of primary and metastatic neoplastic diseases with hsp90-peptide complexes |
US6447780B1 (en) | 1997-02-07 | 2002-09-10 | Fordham University | Prevention of primary and metastatic neoplastic diseases with hsp90-peptide complexes |
US6383494B1 (en) | 1997-02-07 | 2002-05-07 | Fordham University | Methods and composition for eliciting an immune response with gp96-peptide complexes |
US6455048B1 (en) | 1997-02-07 | 2002-09-24 | Fordham University | Prevention of primary and metastatic neoplastic diseases with hsp70-peptide complexes |
US6383493B1 (en) | 1997-02-07 | 2002-05-07 | Fordham University | Methods and compositions for eliciting an immune response with hsp70-peptide complexes |
US6322790B1 (en) | 1997-02-07 | 2001-11-27 | Fordham University | Compositions and methods for eliciting an immune response using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
WO1998042366A1 (en) * | 1997-03-25 | 1998-10-01 | Zetesis S.P.A. | The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf) |
US6255283B1 (en) | 1997-03-25 | 2001-07-03 | Zetesis S.P.A. | Use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (TNF) |
US6524825B1 (en) | 1997-08-05 | 2003-02-25 | Stressgen Biotechnologies, Inc. | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
US7262014B2 (en) | 1997-08-05 | 2007-08-28 | Stressgen Biotechnologies Corporation | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
US6900035B2 (en) | 1997-08-05 | 2005-05-31 | Stressgen Biotechnologies, Inc. | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
US6410027B1 (en) | 1997-12-11 | 2002-06-25 | Fordham University | Methods for preparation of vaccines against cancer |
US6410026B1 (en) | 1997-12-11 | 2002-06-25 | Fordham University | Methods for preparation of vaccines against cancer |
US6406700B1 (en) | 1997-12-11 | 2002-06-18 | Fordham University | Methods for preparation of vaccines against cancer |
US5948646A (en) * | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
US8685384B2 (en) | 1998-02-20 | 2014-04-01 | University Of Miami | Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex |
US6497880B1 (en) | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
US6495347B1 (en) | 1999-07-08 | 2002-12-17 | Stressgen Biotechnologies Corporation | Induction of a Th1-like response in vitro |
US6657055B2 (en) | 1999-07-08 | 2003-12-02 | Stressgen Biotechnologies Corporation | Induction of a Th1-like response in vitro |
US7501125B2 (en) | 2000-01-14 | 2009-03-10 | Whitehead Institute For Biomedical Research | Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
US6875435B2 (en) | 2000-01-14 | 2005-04-05 | Whitehead Institute For Biomedical Research | In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
US7449557B2 (en) | 2000-06-02 | 2008-11-11 | University Of Connecticut Health Center | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
US7211411B2 (en) | 2000-06-26 | 2007-05-01 | Nventa Biopharmaceuticals Corporation | Human papilloma virus treatment |
US6797491B2 (en) | 2000-06-26 | 2004-09-28 | Stressgen Biotechnologies Corporation | Human papilloma virus treatment |
US7754449B2 (en) | 2000-06-26 | 2010-07-13 | Nventa Biopharmaceuticals Corporation | Human papilloma virus treatment |
US6921534B2 (en) | 2001-02-05 | 2005-07-26 | Stressgen Biotechnologies Corporation | Hepatitis B virus treatment |
US7666581B2 (en) | 2001-08-20 | 2010-02-23 | University Of Connecticut Health Center | Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease |
US8541002B2 (en) | 2003-09-12 | 2013-09-24 | Agenus Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
US8475785B2 (en) | 2008-03-03 | 2013-07-02 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
US9238064B2 (en) | 2008-03-03 | 2016-01-19 | University Of Miami | Allogeneic cancer cell-based immunotherapy |
US8968720B2 (en) | 2008-03-20 | 2015-03-03 | University Of Miami | Heat shock protein GP96 vaccination and methods of using same |
US10046047B2 (en) | 2015-02-06 | 2018-08-14 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
US10758611B2 (en) | 2015-02-06 | 2020-09-01 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
US10780161B2 (en) | 2015-02-06 | 2020-09-22 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
Also Published As
Publication number | Publication date |
---|---|
GB9026278D0 (en) | 1991-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2251186A (en) | Polypeptide for use in treatment of autoimmune disease | |
CA1340472C (en) | Universal t-cell epitope derived from p. faciparum circumsporosoite protein | |
CA1325612C (en) | Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions | |
JP2573815B2 (en) | Mycobacterium infection detection synthetic polypeptide | |
IE903899A1 (en) | Vaccine composition with non-immunosuppressive T-cell¹epitope component | |
EP1149115A1 (en) | METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41 | |
EP0811016A1 (en) | Synthetic peptide based immunogens for the treatment of allergy | |
NO167359B (en) | PROCEDURE FOR THE PREPARATION OF A VACCINE AGAINST INFECTION OF HEPATITIS B VIRUS. | |
EP0262710A1 (en) | Use of a peptide for the preparation of compositions for the alleviation, treatment and diagnosis of autoimmune diseases, especially arthritic conditions, compounds related to said peptide, micro-organisms expressing said peptide or a compound related to said peptide, as well as pharmaceutical and diagnostic compositions and test kits | |
WO1996012740A1 (en) | SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY | |
US5858369A (en) | Anti-acids secretory recombinant BCG vaccine | |
Kraus et al. | Renal autoimmune epitope of group A streptococci specified by M protein tetrapeptide Ile-Arg-Leu-Arg. | |
Chong et al. | Identification of T-and B-cell epitopes of the S2 and S3 subunits of pertussis toxin by use of synthetic peptides | |
CN1082053A (en) | Synthetic polypeptide | |
KR100217809B1 (en) | Recombinant bcg vaccine | |
Chong et al. | Structural and functional analysis of the SI subunit of pertussis toxin using synthetic peptides | |
Jin et al. | Long-lasting specific antibodies against P277 induced by mucosal administration of P277 repeat sequences carried by Hsp65 in the absence of adjuvants | |
EP0280576A2 (en) | Synthetic anti-caries vaccine | |
Mishra et al. | Human T-helper cell responses to a synthetic peptide derived from the hepatitis B surface antigen. | |
Thomas et al. | T lymphocyte recognition of peptide antigens: evidence favoring the formation of neoantigenic determinants. | |
WO1994014469A1 (en) | Multivalent ab1 antibodies as vaccines | |
AU2001271124A1 (en) | Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis | |
WO2002000695A2 (en) | Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis | |
Pallen | Bacterial heat-shock proteins and serodiagnosis | |
O'Hern et al. | The use of molecular modelling to delineate B-cell and T-cell epitopes of human sperm-specific LDH-C4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |